The US Food and Drug Administration has approved a long-awaited REMS risk-management programme to inform healthcare providers and patients about the well-known risks of the erythropoiesis-stimulating agents (ESAs) marketed by Amgen and Johnson & Johnson1. The REMS (Risk Evaluation and Mitigation Strategy) includes a training programme called APPRISE for doctors who administer the drugs to cancer patients, which will be launched on 24 March...
Please login to read the full article.
